Literature DB >> 12511758

Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study.

Geert Sulter1, Jan Willem Elting, Marc Langedijk, Natasha M Maurits, Jacques De Keyser.   

Abstract

BACKGROUND AND
PURPOSE: Pathophysiological considerations and observational studies indicate that elevated body temperature, hypoxia, hypotension, and cardiac arrhythmias in the acute phase of ischemic stroke may aggravate brain damage and worsen outcome.
METHODS: Both units were organized with the same standard care and multidisciplinary approach to nursing and rehabilitation. A blinded observer assessed functional outcome at 3 months with the modified Rankin scale (mRS) and Barthel Index (BI). End points were (1) poor outcome, defined as either mRS > or =4 or BI <60 or the need for institutional care and (2) mortality.
RESULTS: Fifty-four patients meeting the inclusion criteria were randomized. The groups were well matched for baseline characteristics, stroke subtype, stroke severity, vascular risk factors, and prognostic factors. Poor outcome was seen in 7 (25.9%) patients in the SCMU group and in 13 (48.1%) in the SU group (P=0.16). Mortality was lower in the SCMU group than in the SU group (1 [3.7%] vs 7 [25.9%]; odds ratio, 0.11 [95% CI, 0.02 to 0.96], P=0.05).
CONCLUSIONS: This pilot study suggests that admission of acute stroke patients to an SCMU may reduce mortality and poor outcome. A larger trial is required to confirm these findings.

Entities:  

Mesh:

Year:  2003        PMID: 12511758     DOI: 10.1161/01.str.0000048148.09143.6c

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

1.  [New developments in German stroke units].

Authors:  J H Faiss; O Busse; E B Ringelstein
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

2.  [European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack : part 2].

Authors:  P D Schellinger; P Ringleb; W Hacke
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

3.  [Regional and national stroke units in Germany: amended certification criteria].

Authors:  D G Nabavi; E B Ringelstein; J Faiss; C Kessler; J Röther; O Busse
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

4.  Significant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST).

Authors:  L J Gray; N Sprigg; P M W Bath; P Sørensen; E Lindenstrøm; G Boysen; P P De Deyn; P Friis; D Leys; R Marttila; J-E Olsson; D O'Neill; B Ringelstein; J-J van der Sande; A G G Turpie
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07-26       Impact factor: 10.154

5.  The latest national clinical guideline for stroke.

Authors:  Shahid A Kausar
Journal:  Clin Med (Lond)       Date:  2017-07       Impact factor: 2.659

Review 6.  [Basics of acute stroke treatment].

Authors:  A Haass
Journal:  Radiologe       Date:  2005-05       Impact factor: 0.635

7.  [Billing based on a case-based lump sum for stroke. Did this lead to discharge of patients in a worse clinical condition?].

Authors:  M Jauss; G F Hamann; D Claus; B Misselwitz; C Kugler; A Ferbert
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

8.  [Management of patients with intracerebral hemorrhages on Austrian Stroke Units: results of the GOG-BIQG Austrian Stroke Units Registry 2003-2007].

Authors:  Raoul Eckhardt; Stefan Schnabl; Michael Brainin
Journal:  Wien Med Wochenschr       Date:  2008

9.  Infarction of the cervical spinal cord following multilevel transforaminal epidural steroid injection: case report and review of the literature.

Authors:  Kenji Muro; Brian O'Shaughnessy; Aruna Ganju
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

10.  Early changes in physiological variables after stroke.

Authors:  Andrew A Wong; Stephen J Read
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.